On this page
How do you assemble an ANDA or 505(b)(2) patent-certification package?
Identify the correct listed drug, proposed product and uses, then reconcile each relevant patent with counsel’s certification or statement determination. Keep that record aligned with proposed labeling and current patent information. Assess notice, evidence of delivery and later amendments as separate actions under the applicable pathway; a completed patent list alone is not the package.
Before you begin
ANDA and 505(b)(2) patent certifications for relied-on listed drugs. Patent scope and notice decisions require qualified legal review.
What you will prepare: A reconciled certification matrix and controlled submission/notice worklist, without unsupported legal assertions.
Establish reliance and the current patent universe
Begin with the listed drug relied on, its application number, product/strength, proposed conditions of use and the current patent listing. Use §314.50(i) for 505(b)(2) applications and §314.94(a)(12) for ANDAs. Record patent-by-patent the relevant listing, expiration information, proposed certification or statement, rationale, counsel owner and date checked.
A search returning no familiar brand name is not evidence that patent information is absent. Match the exact listed drug and current record. Do not treat a patent listing as a judicial determination of validity or infringement.
Distinguish the four certification positions and a use statement
The certification categories address: patent information not filed; patent expired; the date on which the patent will expire; or the position that the patent is invalid, unenforceable or will not be infringed, as applicable under the pathway’s rule. A permitted statement that a method-of-use patent does not claim a use for which approval is sought is a different route, tied to the actual proposed use and labeling.
Have counsel supply the determination and final wording. The writer assembles identifiers, factual references and the approved rationale. Do not choose Paragraph IV because it sounds faster, or a use statement because a proposed label simply omits a phrase. Reconcile labeling, safety implications and the applicable statutory/regulatory conditions.
Treat notice and later changes as separate controlled work
Paragraph IV certifications can trigger notice requirements under §314.52 for 505(b)(2) applications or §314.95 for ANDAs. Establish the triggering event, recipients, permitted method, required content, dispatch evidence and subsequent FDA documentation under the correct pathway. Do not copy a single notice deadline across original applications, amendments and newly listed patents.
Fictional exercise: a patent is added after the team freezes its draft matrix. Recheck the current list and the amendment provisions before filing; preserve why a certification changes or does not. If the precise relied-on listed drug is missing, stop the certification decision and obtain it. A complete matrix with unresolved legal positions is still a draft, not an executed certification.
Keep the patent decision and notice event on separate records
Use the first record for the substantive position and a second for the actions that follow it. Combining both into a single “done” checkbox makes changes difficult to review.
| Patent decision record | Notice/action record |
|---|---|
| Exact relied-on listed drug and product | ANDA or 505(b)(2) pathway and governing notice provision |
| Patent number and dated listing evidence | Actual original-application, amendment or supplement event |
| Relevant proposed use and label version | Trigger document, applicable timing rule and responsible owner |
| Counsel’s certification or statement position | Required recipients and approved delivery method |
| Supporting determination and unresolved issue | Dispatch/receipt evidence and required FDA follow-up |
| Next recheck event | Completion supported by the actual records |
For an original ANDA, inspect §314.95(b)’s acknowledgment-letter and timing provisions; for a 505(b)(2) application, inspect §314.52(b)’s filing boundary. Amendments and supplements have their own provisions. Build the deadline from the actual pathway and event rather than using one generic “20 days from filing” instruction.
Label-change exercise: the initial position uses a method-of-use statement because the proposed labeling excludes the patented use. A later labeling revision adds that use. Reopen the substantive patent analysis before treating the old statement as current, and then assess the resulting certification, notice and amendment work. A change log that only tracks text edits will miss this dependency.
Also distinguish a patent license from a right to reference data. The rules contain specific provisions for patent licensing agreements; possession of a license is not a reason to omit the patent row. Keep the legal determination with its reviewer and use the rights-of-reference guide for separate evidence permissions.
The patent-task overview helps when the request actually concerns the NDA holder’s listing. Preserve dated versions of the matrix so a reviewer can explain why a position changed between submission events.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is a method-of-use statement the same as a Paragraph IV certification?
No. The regulations distinguish a statement concerning a use for which approval is not sought from a certification concerning a relevant patent. Match the actual proposed labeling and use to the appropriate route with counsel. Merely deleting a phrase from a draft label does not establish that the statement is appropriate.
Can the same Paragraph IV notice deadline be copied into every submission plan?
No. Sections 314.52 and 314.95 distinguish pathways and original-application timing from amendment or supplement events. Identify the actual trigger, recipient and delivery requirements before setting the worklist. A generic deadline measured from an internal filing date can miss both the earliest valid notice and the applicable due date.
Does a patent license remove the need for a patent certification?
Not automatically. The ANDA and 505(b)(2) rules contain specific licensing-agreement provisions involving a Paragraph IV certification and a license statement, with additional treatment where the owner consents to approval as of a date. Have counsel apply those provisions to the actual agreement instead of deleting the patent from the matrix.
What should happen when the patent list or proposed use changes before approval?
Reconcile the new information with the existing certification or statement and the applicable amendment provisions. Record the dated change and counsel’s determination, including any conditions or exceptions that affect the response. Do not assume a matrix frozen at original submission remains accurate through the entire review.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 314: drug marketing applications ↗Current part reopened September 22, 2026; §§314.50, 314.53, 314.65, 314.72, 314.94, 314.99, 314.108 and 314.150–162 inspected. Not a general BLA rule.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.3.5.2. A heading identifies placement, not mandatory applicability.